BACKGROUND: Flebogamma 10% DIF represents an evolution of intravenous immune globulin from the previous 5% product to be administered at higher rates and with smaller infusion volumes. Pathogen safety is enhanced by the combination of multiple methods with different mechanisms of action. OBJECTIVE: The objective of this study as to evaluate the efficacy, pharmacokinetics, and safety of Flebogamma 10% DIF for immunoglobulin replacement therapy in primary immunodeficiency diseases (PIDD). METHODS: Flebogamma 10% DIF was administered to 46 subjects with well-defined PIDD at a dose of 300-600 mg/kg every 21-28 days for 12 months. RESULTS: Serious bacterial infection rate was 0.025/subject/year. Half-life in serum of the administered IgG was approximately 35 days. No serious treatment-related adverse event (AE) occurred in any patient. Most of the potentially treatment-related AEs occurred during the infusion, accounting for 20% of the 601 infusions administered. CONCLUSIONS: Flebogamma 10% DIF is efficacious and safe, has adequate pharmacokinetic properties, and is well-tolerated for the treatment of PIDD.
BACKGROUND:Flebogamma 10% DIF represents an evolution of intravenous immune globulin from the previous 5% product to be administered at higher rates and with smaller infusion volumes. Pathogen safety is enhanced by the combination of multiple methods with different mechanisms of action. OBJECTIVE: The objective of this study as to evaluate the efficacy, pharmacokinetics, and safety of Flebogamma 10% DIF for immunoglobulin replacement therapy in primary immunodeficiency diseases (PIDD). METHODS:Flebogamma 10% DIF was administered to 46 subjects with well-defined PIDD at a dose of 300-600 mg/kg every 21-28 days for 12 months. RESULTS: Serious bacterial infection rate was 0.025/subject/year. Half-life in serum of the administered IgG was approximately 35 days. No serious treatment-related adverse event (AE) occurred in any patient. Most of the potentially treatment-related AEs occurred during the infusion, accounting for 20% of the 601 infusions administered. CONCLUSIONS:Flebogamma 10% DIF is efficacious and safe, has adequate pharmacokinetic properties, and is well-tolerated for the treatment of PIDD.
Authors: Mark Ballow; Paul J Pinciaro; Timothy Craig; Gary Kleiner; James Moy; Hans D Ochs; John Sleasman; William Smits Journal: J Clin Immunol Date: 2016-06-08 Impact factor: 8.317
Authors: Inga A Laursen; Lene Blou; John S Sullivan; Peter Bang; Flemming Balstrup; Gunnar Houen Journal: Transfus Med Hemother Date: 2014-04-14 Impact factor: 3.747
Authors: Jennifer Heimall; Junliang Chen; Joseph A Church; Rhonda Griffin; Isaac Melamed; Gary I Kleiner Journal: J Clin Immunol Date: 2016-06-25 Impact factor: 8.317
Authors: Richard L Wasserman; Joseph A Church; Mark Stein; James Moy; Martha White; Steven Strausbaugh; Harry Schroeder; Mark Ballow; James Harris; Isaac Melamed; David Elkayam; William Lumry; Daniel Suez; Syed M Rehman Journal: J Clin Immunol Date: 2012-03-06 Impact factor: 8.317
Authors: Richard L Wasserman; William Lumry; James Harris; Robyn Levy; Mark Stein; Lisa Forbes; Charlotte Cunningham-Rundles; Isaac Melamed; Ai Lan Kobayashi; Wei Du; Roger Kobayashi Journal: J Clin Immunol Date: 2016-06-20 Impact factor: 8.317
Authors: Michael Borte; Isaac R Melamed; Grazyna Pulka; Barbara Pyringer; Alan P Knutsen; Hans D Ochs; Roger H Kobayashi; Ai Lan Kobayashi; Sudhir Gupta; Magdalena Strach; William Smits; Anna Pituch-Noworolska; James N Moy Journal: J Clin Immunol Date: 2017-07-29 Impact factor: 8.317
Authors: Elena E Perez; Jacques Hébert; Anne K Ellis; Oral Alpan; William R Lumry; Ralph Shapiro; Daniel Suez; J Fernando Mandujano; Richard L Wasserman Journal: Front Immunol Date: 2021-07-08 Impact factor: 7.561